Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib maintenance after autologous stem cell transplantation in core-binding factor AML
ChiCTR2000034990Phase 4Recruiting
- Sponsor
- Affiliated Hospital of Southwest Medical University
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in core binding factor acute myeloid leukemia comparing Dasatinib group with Observation control group (2 arms). Primary endpoints: overall survival and disease-free survival. Started Jul 2020; status: recruiting.
02
Drugs
dasatinib
03
Conditions
core binding factor acute myeloid leukemia
Beyond the preview
Go deeper on ChiCTR2000034990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034990.